Compare Robinhood Markets, Inc. (HOOD) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Incyte Corporation — how do they compare? Robinhood Markets, Inc. trades at $109.02 (market cap $96.21B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Robinhood Markets, Inc. is far larger — about 4.2× Incyte Corporation's market cap, and Robinhood Markets, Inc. is more actively traded (22,572,153 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and Incyte Corporation for 33 Days on average.
| HOOD | INCY | |
|---|---|---|
Market Cap | $96.21B | $22.85B |
Volume | 22,572,153 | 1,927,029 |
Sector | Financials | Health |
52-Week High | $147.08 | $129.93 |
52-Week Low | $65.16 | $83.80 |
Typical Hold Time | 75 Days | 33 Days |
Enterprise Value | $102.75B | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $107.01, down 2.28% today, as the stock consolidates near pivot point support at $107. The company shows strong fundamental momentum with revenue growing from $3.0B in 2024 to $4.5B in 2025 and net income reaching $1.88B. Recent announcements include plans for 24/7 stock trading and expanded product offerings, positioning the company for continued growth in the expanding e-brokerage market.
HOOD presents a compelling growth story with robust profitability metrics and analyst optimism, though elevated valuation ratios and execution risks warrant caution. The stock's technical setup suggests near-term consolidation with upside potential toward the $137.53 consensus price target, supported by strong institutional sentiment and innovative business initiatives.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
